---
title: "The United States, Eli Lilly, and Novo Nordisk AS announced an agreement to lower the price of GLP-1 weight loss drugs, with both companies pricing it at $245 per month"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/264698319.md"
description: "The United States, Eli Lilly, and Novo Nordisk AS announced an agreement to lower the price of GLP-1 weight loss drugs, with the two companies pricing it at $245 per month. Risk warning and disclaimer: The market has risks, and investment requires caution. This article does not constitute personal investment advice and does not take into account the specific investment goals, financial situation, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article align with their specific circumstances. Investing based on this is at one's own risk"
datetime: "2025-11-06T17:05:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/264698319.md)
  - [en](https://longbridge.com/en/news/264698319.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/264698319.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/264698319.md) | [繁體中文](https://longbridge.com/zh-HK/news/264698319.md)


# The United States, Eli Lilly, and Novo Nordisk AS announced an agreement to lower the price of GLP-1 weight loss drugs, with both companies pricing it at $245 per month

The United States, Eli Lilly, and Novo Nordisk AS announced an agreement to lower the price of GLP-1 weight loss drugs, with both companies pricing it at $245 per month.

Risk Warning and Disclaimer

The market has risks, and investment should be cautious. This article does not constitute personal investment advice and does not take into account the specific investment goals, financial situation, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article are suitable for their specific circumstances. Investment based on this is at one's own risk

### 相关股票

- [Novo Nordisk AS (NVO.US)](https://longbridge.com/zh-CN/quote/NVO.US.md)
- [Eli Lilly (LLY.US)](https://longbridge.com/zh-CN/quote/LLY.US.md)

## 相关资讯与研究

- [FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market](https://longbridge.com/zh-CN/news/281394441.md)
- [Novo Nordisk slashes Wegovy prices to court uninsured patients](https://longbridge.com/zh-CN/news/281206892.md)
- [Novo Nordisk stock surges 4%: can NHS boost offset pricing pressure?](https://longbridge.com/zh-CN/news/281358134.md)
- [Novo Nordisk Voucher Win Meets Rising Scrutiny Of FDA Review Program](https://longbridge.com/zh-CN/news/280885256.md)
- [Novo Nordisk Seeks to Expand Reach of Weight Loss Drug in Japan](https://longbridge.com/zh-CN/news/279766298.md)